Development and Application of Physiologically Based Modeling of Lymphatic Absorption and Disposition of Allopregnanolone to Support of Model-Informed Drug Development of Lymphatic Glyph Prodrugs
Research
Population Pharmacokinetic Modeling of Oral GlyphAllo in Healthy Volunteers Strengthens Evidence for Lymphatic Absorption of Glyph Prodrugs
GlyphAgo demonstrated 6.8-fold increased bioavailability and 10-fold reduced variability versus unmodified agomelatine in healthy volunteers at doses projected to mitigate liver exposure
Prediction of Human Pharmacokinetic Profiles of Glyph Platform Prodrugs Using Animal and Human Data via a Semi-mechanistic Pharmacokinetic Model
Unlocking Medicines for Neuropsychiatry by Enhancing Oral Absorption Using a Lymphatic-targeting Prodrug Technology
GlyphAllo, a Novel, Orally Bioavailable Prodrug of Allopregnanolone, Induces an EEG Profile Consistent with GABAA Positive Allosteric Modulation in Healthy Volunteers
Predicted Liver Safety of GlyphAgo, a Lymphatic-targeting Prodrug of Agomelatine That Avoids First-pass Metabolism
Frequency of Rater-based Efficacy Assessments Correlated with Magnitude of Placebo Response in Generalized Anxiety Disorder Trials
GlyphCBD (SPT-310), a Lymphatic-Targeting Prodrug of Cannabidiol, Significantly Inhibits Seizure Activity in the Maximal Electroshock Seizure Model
SPT-320, a First-in-Class Prodrug of Agomelatine that Avoids
First-Pass Hepatic Metabolism via Lymphatic System Absorption
